Leni / Research, in context
Sexual-function research
A defined clinical population matters. This topic explains why findings from sexual-function trials should not be broadened into general enhancement claims.
About this publication. Published by Leni Health, a laboratory research materials supplier. These pages review published literature; they do not offer products, recommend personal use or report clinical trials conducted by Leni.
Which population does the evidence describe?
Bremelanotide trials examined a specific diagnosed condition in a defined group of women. Those eligibility criteria remain part of the result.
What is the outcome?
Desire-related scores, distress and event counts are different measures. Their interpretation depends on the study design and comparator.
What stays in the review?
Adverse effects and limitations belong alongside efficacy findings. A research compound name does not establish equivalence to a regulated medicine.
Evidence map
What was studied. What it can tell us.
This is a map of selected evidence, not a ranking of products or treatments.
| Research subject | Study setting & finding | Interpretation & limits | Source |
|---|---|---|---|
| Bremelanotide / PT-141 |
Randomised clinical trials The RECONNECT programme investigated acquired, generalised hypoactive sexual desire disorder in premenopausal women. |
The findings are population-specific, include adverse effects and should not be translated into general sexual-performance promises. | Study record ↗ |
Go deeper into the evidence.
Read the existing compound reviews, including study details, mixed findings and original sources.
How to read this review
This is a selected narrative synthesis of the research already reviewed in the Leni library, with primary sources linked for further reading. It is not an exhaustive systematic review, a treatment comparison or medical advice. Study findings concern the intervention, model and population tested. They do not establish the safety or quality of a separately supplied material.
Topic review: 12 October 2026. Existing compound reviews retain their own evidence dates and source-access notes. No independent clinical review is claimed.
Read our evidence and editorial approach →